Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Receivables (2016 - 2025)

Coherus Oncology's Receivables history spans 12 years, with the latest figure at $18.4 million for Q4 2025.

  • For Q4 2025, Receivables fell 84.94% year-over-year to $18.4 million; the TTM value through Dec 2025 reached $18.4 million, down 84.94%, while the annual FY2025 figure was $18.4 million, 84.94% down from the prior year.
  • Receivables for Q4 2025 was $18.4 million at Coherus Oncology, down from $250.5 million in the prior quarter.
  • Across five years, Receivables topped out at $313.6 million in Q2 2024 and bottomed at $18.4 million in Q4 2025.
  • The 5-year median for Receivables is $129.7 million (2021), against an average of $153.3 million.
  • The largest annual shift saw Receivables surged 180.06% in 2024 before it crashed 84.94% in 2025.
  • A 5-year view of Receivables shows it stood at $123.0 million in 2021, then fell by 10.61% to $110.0 million in 2022, then skyrocketed by 136.92% to $260.5 million in 2023, then plummeted by 53.04% to $122.3 million in 2024, then plummeted by 84.94% to $18.4 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Receivables are $18.4 million (Q4 2025), $250.5 million (Q3 2025), and $119.6 million (Q2 2025).